Studies in patients with hyperlipidaemia: clinical correlates and response to drug therapy.

Abstract

by Say Tung Kun.Thesis (M.Phil.)--Chinese University of Hong Kong, 1998.Includes bibliographical references (leaves 80-92).Abstract also in Chinese.Title --- p.iTable of Contents --- p.iiList of tables --- p.viList of abbreviations --- p.viiiAcknowledgements --- p.xiAbstract --- p.xiiChapter Chapter 1 --- Introduction --- p.1Chapter 1.1 --- Lipids: their nature and function in man --- p.1Chapter 1.2 --- Lipid metabolism --- p.2Chapter 1.3 --- The definition and classification of hyperlipidaemia --- p.3Chapter 1.3.1 --- The definition of hyperlipidaemia --- p.3Chapter 1.3.2 --- Lipid levels and diet in Hong Kong and other Chinese populations --- p.5Chapter 1.3.3 --- The classification of hyperlipidaemia --- p.8Chapter 1.3.4 --- The primary hyperlipidaemias: Genetic disorders of lipid metabolism --- p.8Chapter 1.3.5 --- The secondary causes of hyperlipidaemia --- p.8Chapter 1.4 --- The signs and symptoms of hyperlipidaemia --- p.10Chapter 1.4.1 --- The signs of hyperlipidaemia --- p.10Chapter 1.4.1.1 --- Corneal arcus --- p.10Chapter 1.4.1.2 --- Xanthomata --- p.11Chapter 1.4.1.3 --- Xanthelasmata --- p.11Chapter 1.4.2 --- The symptoms of hyperlipidaemia --- p.12Chapter 1.5 --- The investigations and monitoring of hyperlipidaemia during studies of drug treatment --- p.12Chapter 1.5.1 --- The clinical investigation of hyperlipidaemia --- p.12Chapter 1.5.2 --- The clinical and laboratory monitoring of hyperlipidaemia --- p.13Chapter 1.5.2.1 --- The clinical monitoring of hyperlipidaemia --- p.13Chapter 1.5.2.2 --- The laboratory monitoring of hyerlipidaemia --- p.13Chapter 1.6 --- The therapy of hyperlipidaemia --- p.13Chapter 1.6.1 --- The response to lipid-lowering drug therapy --- p.14Chapter 1.6.1.1 --- The response to the flbric acid derivatives --- p.15Chapter 1.6.2 --- Detection of hyperlipidaemia and benefits of treatment --- p.19Chapter 1.6.3 --- The significance of the present studies --- p.21Chapter Chapter 2 --- Hyperlipidaemia: relationship to other diseases --- p.23Chapter 2.1 --- Atherosclerosis --- p.23Chapter 2.2 --- Vascular Insufficiency Diseases --- p.24Chapter 2.3 --- Hypertension --- p.25Chapter 2.4 --- Diabetes mellitus --- p.26Chapter 2.5 --- Thyroid disorders --- p.30Chapter 2.6 --- Liver disease --- p.31Chapter 2.7 --- Pancreatitis --- p.32Chapter 2.8 --- Renal disease --- p.32Chapter 2.8.1 --- Nephrotic syndrome --- p.32Chapter 2.8.2 --- Chronic renal failure --- p.33Chapter 2.8.3 --- Renal transplant patients --- p.33Chapter Chapter 3 --- Patients and methods in the lipid studies --- p.34Chapter 3.1 --- Characteristics of patients with hypertriglyceridaemia in Hong Kong --- p.34Chapter 3.2 --- Clinical and laboratory methods to measure the response to drug treatment --- p.37Chapter 3.2.1 --- Clinical methods to assess the response to drug treatment --- p.37Chapter 3.2.1.1 --- History --- p.37Chapter 3.2.1.2 --- Physical examination --- p.38Chapter 3.2.1.3 --- Clinical measurement --- p.39Chapter 3.3 --- The laboratory methods to measure the lipid response to drug treatment --- p.39Chapter 3.2.1 --- The methodology for the extended lipid profile --- p.40Chapter 3.3.2 --- Statistical analysis --- p.41Chapter Chapter 4 --- Gemfibrozil dose-response study --- p.43Chapter 4.1 --- Dose-response study of gemfibrozil in Chinese patients with combined hyperlipidaemia --- p.43Chapter 4.1.1 --- Introduction --- p.43Chapter 4.1.2 --- Patients --- p.44Chapter 4.1.3 --- Results --- p.45Chapter 4.1.4 --- Discussion --- p.51Chapter Chapter 5 --- Gemfibrozil 900 mg tablet study --- p.53Chapter 5.1 --- Assessment of the efficacy and tolerability of a new formulation of gemfibrozil as a 900 mg tablet in the treatment of hyperlipidaemia --- p.53Chapter 5.2 --- Patients recruited --- p.53Chapter 5.3 --- Methods --- p.54Chapter 5.4 --- Results --- p.54Chapter 5.4.1 --- Tolerability --- p.54Chapter 5.4.2 --- Efficacy --- p.55Chapter 5.5 --- Discussion --- p.61Chapter Chapter 6 --- Bezafibrate study --- p.64Chapter 6.1 --- Assessment of the efficacy and tolerability of bezafibrate in the treatment of hyperlipidaemia --- p.64Chapter 6.2 --- Introduction --- p.64Chapter 6.3 --- Patients --- p.65Chapter 6.4 --- Results of bezafibrate study --- p.66Chapter 6.4.1. --- Tolerability --- p.66Chapter 6.4.2. --- Efficacy --- p.66Chapter 6.5. --- Discussion --- p.73Chapter Chapter 7 --- Discussion and Conclusions --- p.75Chapter 7.1 --- "Introduction: the two study drugs, gemfibrozil and bezafibrate" --- p.75Chapter 7.2 --- Gemfibrozil --- p.76Chapter 7.3 --- Bezafibrate --- p.77Chapter 7.4 --- Conclusion --- p.78References --- p.80Appendix I. Abstracts relating to these studies from presentations at national and international meetings --- p.93Appendix II. Side effect questionnaire used in the studies --- p.9